Quarterly report pursuant to Section 13 or 15(d)

Condensed Consolidated Statements of Operations and Comprehensive Loss (Unaudited)

v3.24.1.1.u2
Condensed Consolidated Statements of Operations and Comprehensive Loss (Unaudited) - USD ($)
3 Months Ended
Mar. 31, 2024
Mar. 31, 2023
Operating Expenses:    
Research and development $ 365,186 $ 578,309
Research and development - related parties 170,542 216,684
General and administrative 1,556,740 4,008,852
Total Operating Expenses 2,092,468 4,803,845
Loss From Operations (2,092,468) (4,803,845)
Other (Expense) Income:    
Other income 1,039,364  
Interest expense (16,449) (11,556)
Change in fair value of derivative liabilities (191) 53,323
Total Other (Expense) Income, Net 1,022,724 41,767
Loss Before Income Taxes (1,069,744) (4,762,078)
Income tax benefit
Net Loss (1,069,744) (4,762,078)
Other Comprehensive Income (Loss):    
Foreign currency translation adjustments 6,460 663
Total Comprehensive Loss $ (1,063,284) $ (4,761,415)
Basic and Diluted Net Loss per Common Share    
Basic (in Dollars per share) $ (1.68) $ (24.15)
Diluted (in Dollars per share) $ (1.68) $ (24.15)
Weighted Average Number of Common Shares Outstanding:    
Basic (in Shares) 638,339 197,219
Diluted (in Shares) 638,339 197,219